4 news items
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
1 Aug 24
and regulations; market conditions; the impact of pandemics and other health crises on Zymeworks' business, research and clinical development plans
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
22 Jul 24
of pandemics and other health crises on Zymeworks' business, research and clinical development plans and timelines and results of operations, including impact
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
17 Jun 24
of pandemics and other health crises on Zymeworks' business, research and clinical development plans and timelines and results of operations, including
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
10 Jun 24
of pandemics and other health crises on Zymeworks' business, research and clinical development plans and timelines and results of operations, including
- Prev
- 1
- Next